BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34504486)

  • 1. Enhanced CXCR4 Expression of Human CD8
    Burkard T; Dreis C; Herrero San Juan M; Huhn M; Weigert A; Pfeilschifter JM; Radeke HH
    Front Immunol; 2021; 12():668884. PubMed ID: 34504486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Values of CD38
    Zhang M; Yang J; Zhou J; Gao W; Zhang Y; Lin Y; Wang H; Ruan Z; Ni B
    Immunol Invest; 2019 Jul; 48(5):466-479. PubMed ID: 30689488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration.
    Wang W; Graeler MH; Goetzl EJ
    FASEB J; 2005 Oct; 19(12):1731-3. PubMed ID: 16046470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of CXCR4 expression on human CD8+ T cells during peripheral differentiation.
    Kobayashi N; Takata H; Yokota S; Takiguchi M
    Eur J Immunol; 2004 Dec; 34(12):3370-8. PubMed ID: 15549771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer.
    Wu P; Zhao L; Chen Y; Xin Z; Lin M; Hao Z; Chen X; Chen D; Wu D; Chai Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3603-3616. PubMed ID: 33934206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
    Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
    Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
    Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue Cytokine IL-33 Modulates the Cytotoxic CD8 T Lymphocyte Activity During Nutrient Deprivation by Regulation of Lineage-Specific Differentiation Programs.
    Dreis C; Ottenlinger FM; Putyrski M; Ernst A; Huhn M; Schmidt KG; Pfeilschifter JM; Radeke HH
    Front Immunol; 2019; 10():1698. PubMed ID: 31396219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
    Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
    J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities.
    Bahri R; Bollinger A; Bollinger T; Orinska Z; Bulfone-Paus S
    PLoS One; 2012; 7(9):e45234. PubMed ID: 23028866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting
    Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
    Front Immunol; 2021; 12():738958. PubMed ID: 34721405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
    Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
    Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
    Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
    J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
    Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
    Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.